Display options
Share it on

Ther Adv Musculoskelet Dis. 2017 Sep;9(9):213-229. doi: 10.1177/1759720X17719850. Epub 2017 Aug 01.

Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.

Therapeutic advances in musculoskeletal disease

Arduino A Mangoni, Leena R Baghdadi, E Michael Shanahan, Michael D Wiese, Sara Tommasi, David Elliot, Richard J Woodman

Affiliations

  1. Department of Clinical Pharmacology, School of Medicine, Flinders University and Flinders Medical Centre, Bedford Park, SA 5042, Australia.
  2. Department of Clinical Pharmacology, School of Medicine, Flinders University and Flinders Medical Centre, Adelaide, Australia.
  3. Department of Rheumatology, Flinders University and Southern Adelaide Local Health Network, Adelaide, Australia.
  4. School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, Australia.
  5. Centre for Epidemiology and Biostatistics, School of Medicine, Flinders University, Adelaide, Australia.

PMID: 28932292 PMCID: PMC5600310 DOI: 10.1177/1759720X17719850

Abstract

BACKGROUND: Methotrexate (MTX) treatment in rheumatoid arthritis (RA) has been associated with lower cardiovascular risk compared to other disease-modifying antirheumatic drugs (DMARDs). We sought to identify whether the MTX-associated cardioprotection involves changes in blood pressure (BP) and/or arterial function.

METHODS: Clinic and 24-hour peripheral and central systolic and diastolic BP (SBP and DBP), augmentation index (AIx), pulse wave velocity (PWV) and plasma asymmetric dimethylarginine (ADMA) were assessed in RA patients on stable treatment with either MTX ± other DMARDs (MTX group,

RESULTS: After adjusting for visit, age, gender, body mass index, folic acid use and 28-joint disease activity score, the MTX group had significantly lower clinic peripheral SBP (-7.7 mmHg, 95% CI -13.2 to -2.3,

CONCLUSIONS: RA patients on MTX treatment had significantly lower clinic and 24-hour peripheral and central BP compared to those who did not take MTX. The lower BP with MTX may be related to differences in PWV, but not in AIx or ADMA concentrations. Further longitudinal studies including randomized controlled trials are warranted to confirm these findings, to identify other possible mechanisms responsible for the effects of MTX on BP and PWV, and to establish whether these effects might account for the reduced cardiovascular risk with MTX.

Keywords: asymmetric dimethylarginine; augmentation index; blood pressure; disease-modifying antirheumatic drugs; methotrexate; pulse wave velocity; rheumatoid arthritis

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

  1. J Am Heart Assoc. 2015 Nov 13;4(11):null - PubMed
  2. Ann Rheum Dis. 2010 Sep;69(9):1580-8 - PubMed
  3. Clin Rheumatol. 2009 Oct;28(10):1217-20 - PubMed
  4. Blood Press Monit. 2012 Jun;17(3):128-31 - PubMed
  5. Arthritis Care Res (Hoboken). 2012 May;64(5):640-7 - PubMed
  6. Eur Heart J. 2014 Jul;35(26):1719-25 - PubMed
  7. Am J Cardiol. 2012 May 1;109(9):1383-4 - PubMed
  8. Arthritis Rheum. 1995 Jan;38(1):44-8 - PubMed
  9. Eur J Intern Med. 2015 Dec;26(10):835-42 - PubMed
  10. Br J Clin Pharmacol. 2001 Jun;51(6):507-22 - PubMed
  11. Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H2167-72 - PubMed
  12. PLoS One. 2015 Feb 17;10(2):e0117952 - PubMed
  13. Lancet. 2012 Dec 15;380(9859):2224-60 - PubMed
  14. Arthritis Care Res (Hoboken). 2017 Jan;69(1):51-57 - PubMed
  15. J Clin Lab Anal. 2011;25(3):198-202 - PubMed
  16. J Hypertens. 1996 May;14(5):557-63 - PubMed
  17. Blood Press Monit. 2000 Aug;5(4):233-8 - PubMed
  18. Eur Heart J. 2006 Nov;27(21):2588-605 - PubMed
  19. Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):303-19 - PubMed
  20. Am J Hypertens. 2005 Feb;18(2 Pt 1):220-6 - PubMed
  21. Cancer Res. 1964 Jan;24:105-13 - PubMed
  22. Atherosclerosis. 2016 Aug;251:438-444 - PubMed
  23. Immunopharmacology. 2000 Apr;47(1):35-44 - PubMed
  24. Am J Cardiol. 2011 Nov 1;108(9):1362-70 - PubMed
  25. Blood Press Monit. 1998 Aug;3(4):255-260 - PubMed
  26. J Hypertens. 2014 Feb;32(2):216-24 - PubMed
  27. Atherosclerosis. 2012 Oct;224(2):309-17 - PubMed
  28. Blood Press Monit. 2010 Aug;15(4):229-31 - PubMed
  29. Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3227-45 - PubMed
  30. Arthritis Res Ther. 2006;8(5):R151 - PubMed
  31. Hypertension. 2001 Oct;38(4):932-7 - PubMed
  32. Blood Press Monit. 2010 Aug;15(4):225-8 - PubMed
  33. Blood Press Monit. 2005 Oct;10(5):239-42 - PubMed
  34. Br J Clin Pharmacol. 2002 Feb;53(2):189-92 - PubMed
  35. Circulation. 2006 Mar 7;113(9):1213-25 - PubMed
  36. Autoimmun Rev. 2014 Nov;13(11):1102-8 - PubMed
  37. Am J Nurs. 1978 Jun;78(6):1039-40 - PubMed
  38. J Intern Med. 2002 Dec;252(6):497-503 - PubMed
  39. PLoS One. 2015 Jun 26;10 (6):e0130709 - PubMed
  40. Inflamm Res. 2005 Jul;54(7):273-80 - PubMed
  41. Ann Rheum Dis. 2001 Aug;60(8):729-35 - PubMed
  42. Hypertension. 2001 Aug;38(2):227-31 - PubMed
  43. J Hypertens. 2012 May;30(5):842-51 - PubMed
  44. J Hypertens. 2012 Feb;30(2):267-8 - PubMed
  45. J Clin Invest. 2003 Jun;111(12):1805-12 - PubMed
  46. Arthritis Rheum. 2006 Jun;54(6):1847-55 - PubMed
  47. Joint Bone Spine. 2013 Jan;80(1):29-33 - PubMed
  48. Arthritis Care Res (Hoboken). 2016 Dec 20;:null - PubMed
  49. Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S5-8 - PubMed
  50. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27 - PubMed
  51. Stroke. 2001 Feb;32(2):454-60 - PubMed
  52. Arch Drug Inf. 2009 Jun;2(2):34-40 - PubMed
  53. J Hum Hypertens. 2010 Aug;24(8):498-504 - PubMed
  54. Med J Aust. 2016 Jul 18;205(2):85-9 - PubMed
  55. Arterioscler Thromb Vasc Biol. 2005 May;25(5):932-43 - PubMed
  56. BMJ. 2004 Jun 26;328(7455):1519 - PubMed
  57. Ann Rheum Dis. 2015 Feb;74(2):408-14 - PubMed
  58. Trans Am Clin Climatol Assoc. 2013;124:16-25 - PubMed
  59. J Rheumatol. 2007 Dec;34(12 ):2388-94 - PubMed
  60. Blood Press Monit. 2013 Jun;18(3):173-6 - PubMed
  61. Curr Med Chem. 2015 ;22(24):2871-901 - PubMed
  62. Curr Neuropharmacol. 2016;14 (7):665-73 - PubMed
  63. Circulation. 2006 Sep 12;114(11):1185-92 - PubMed
  64. Psychol Med. 1988 Nov;18(4):1007-19 - PubMed
  65. Nutr Metab Cardiovasc Dis. 2010 Jun;20(5):341-9 - PubMed
  66. Curr Atheroscler Rep. 2012 Oct;14(5):460-8 - PubMed
  67. J Hypertens. 2012 Feb;30(2):253-66 - PubMed
  68. J Am Geriatr Soc. 2003 Aug;51(8):1105-10 - PubMed
  69. Hypertension. 2011 Nov;58(5):825-32 - PubMed
  70. J Rheumatol. 1997 Mar;24(3):445-51 - PubMed
  71. Rheumatology (Oxford). 2007 Sep;46(9):1477-82 - PubMed
  72. Arthritis Rheum. 1983 Nov;26(11):1346-53 - PubMed
  73. Circ Res. 2015 Mar 13;116(6):1058-73 - PubMed
  74. Eur Heart J. 2010 Aug;31(15):1865-71 - PubMed
  75. Lancet. 2001 Nov 17;358(9294):1682-6 - PubMed
  76. Ann Rheum Dis. 2015 Mar;74(3):480-9 - PubMed

Publication Types